Bisindolylmaleimide I, HCl is a water soluble form of Bisindolylmaleimide I (sc-24003); a staurosporine (sc-3510) inspired molecule, which has been shown to display equally potent inhibition, but with vastly superior selectivity for all of the known isoforms of PKC (IC50 = 8-20 nM). Inhibition is competitive with respect to ATP, which suggests that Bisindolylmaleimide I occupies the ATP binding domain of the PKC isoforms. This compound has been used to selectively probe for PKC-mediated pathways for transduction of hormone, cytokine, and growth factor signals. Shown to inhibit PKC (protein kinase C) within intact platelets and T cells, Fas-mediated apoptosis, and T cell-mediated autoimmune diseases. Bisindolylmaleimide I, HCl is an inhibitor of PKC α, PKC β, PKCδ, PKC ε and PKC γ.
1. Toullec, D., et al. 1991. J. Biol. Chem. 266: 15771-15781. PMID: 1874734
2. Martiny-Baron, G., et al. 1993. J. Biol. Chem. 268: 9194-9197. PMID: 8486620
3. Kiss, Z., et al. 1995. Biochim. Biophys. Acta. 1265: 93-95. PMID: 7857990
4. Zhou, T., et al. 1999. Nat. Med. 5: 42-48. PMID: 9883838
See how others have used Bisindolylmaleimide I, HCl (CAS 176504-36-2). Click on the entry to view the PubMed entry .
PMID: # 31087358 2019. Mol. Carcinog. 58: 1492-1501.
PMID: # 28115242 Jeong, CH.|Seok, JS.|Petriello, MC.|Han, SG.| et al. 2017. Toxicology. 379: 31-39.
PMID: # 27353086 Lange, S.|Gehmlich, K.|Lun, AS.|Blondelle, J.|Hooper, C.|Dalton, ND.|Alvarez, EA.|Zhang, X.|Bang, ML.|Abassi, YA.|Dos Remedios, CG.|Peterson, KL.|Chen, J.|Ehler, E.| et al. 2016. Nat Commun. 7: 12120.
PMID: # 21148485 Chen S, Evans HG, Evans DR. et al. 2011. J Biol Chem. 286: 10201-10209.
PMID: # 15978263 Hamel, C. et al. 2005. Life Sci. 77: 1069-1081.
PMID: # 16227274 Chang, M. et al. 2005. J. Virol. 79: 13538-13547.
PMID: # 12361872 Hendricson, AW. et al. 2002. Hear. Res. 172: 99-99-109109.
PMID: # 12468027 Smith, FL. et al. 2002. Brain Res. 958: 28-35.
PMID: # 11882295 Nair, KS. et al. 2002. Curr. Biol. 12: 421-425.
PMID: # 10532947 Bodart, V. et al. 1999. Circ. Res. 85: 796-802.